Today, PDX Pharmaceuticals, in collaboration with the Biomedical Engineering Department of Oregon Health and Science University, was awarded a phase I SBIR grant from the National Center for Advancing Translational Sciences to support our pre-clinical research activity during the period of Aug 2017 – Aug 2018. The grant is entitled “Development of topical formulation of siRNA-nanoparticle for treating skin diseases”, R43TR001906.
This proposal aims at developing a topical formulation of siRNA-nanoparticle that delivers siRNA to treat skin fibrosis. Our platform has inherent antioxidant and anti-inflammatory properties, further benefitting the treatment of skin fibrosis for which there is no effective treatment. Upon completion, the platform will have broad applicability since siRNA can be designed to knock down any gene responsible for other diseases, such as psoriasis, skin disorders, and skin cancers, see PDX-002.